This roundtable series considers multiple therapies from published clinical trials for patients with relapsed/refractory metastatic clear cell renal cell carcinoma, as discussed by key opinion leaders and participants at virtual live events.
Discussing Tolerability of Tivozanib as Third-Line Therapy for mRCCOctober 24th 2022
During a Targeted Oncology case-based roundtable event, Randy F. Sweis, MD, discussed with participants their experience with the tolerability of tivozanib for recurrent advanced renal cell carcinoma. This is the first of 2 articles based on this event.
Second-Line Considerations After Immune Toxicity From Prior RCC TherapyDecember 21st 2022
During a Targeted Oncology case-based roundtable event, Saby George, MD, discussed which second-line therapy would be appropriate for a patient who discontinued frontline immunotherapy/tyrosine kinase inhibitor therapy due to immune-related toxicity.
Factors Favoring Tivozanib as Third-Line Therapy for Advanced RCCJanuary 2nd 2023
During a Targeted Oncology case-based roundtable event, Saby George, MD, and participants discussed the role of tivozanib and other later-line options in patients with advanced renal cell carcinoma.
Discussing the Role of Tivozanib in the Third-Line of RCC TreatmentMarch 14th 2023
With updated data for the usefulness of tivozanib, patients with recurrent clear cell renal carcinoma have an effective option for treatment in a treatment landscape previously without many treatment options.